| 000 | 00000nam 2200000za 4500 |
| 001 | 9.848199 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107153622 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 171201s2018 onca o f000 0 eng d |
|---|
| 020 | |a9780660240954|z9780660240961 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aNR16-188/2017E-PDF |
|---|
| 110 | 2 |aNational Research Council Canada. |
|---|
| 245 | 10|aPreclinical in vivo facility |h[electronic resource]. |
|---|
| 260 | |a[Ottawa] : |bNational Research Council Canada, |c2018. |
|---|
| 300 | |a[2] p. : |bcol. ill. |
|---|
| 500 | |aIssued also in French under title: Installation préclinique in vivo. |
|---|
| 500 | |aCaption title. |
|---|
| 500 | |a"March 2018." |
|---|
| 520 | |a"The Preclinical in vivo Facility leverages the NRC’s expertise in cell and molecular biology, chemistry, nanotechnology, computer and imaging science to evaluate biologics and vaccines in a variety of disease and challenge models. Our expertise and state-of-the-art equipment enables our clients to validate their biologics and vaccine design approaches and obtain a clear picture of the preclinical safety and efficacy of their products"--P. [1]. |
|---|
| 530 | |aIssued also in print format. |
|---|
| 693 | 4|aPharmaceutical biotechnology |
|---|
| 775 | 08|tInstallation préclinique in vivo |w(CaOODSP)9.848201 |
|---|
| 776 | 0#|tPreclinical in vivo facility |w(CaOODSP)9.848200 |
|---|
| 856 | 40|qPDF|s160 KB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-188-2017-eng.pdf |
|---|